中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 3
Mar.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(3): 622-628

Clinical effect of simultaneous surgical resection of hepatic and pancreatic lesions versus systemic chemotherapy in treatment of resectable pancreatic cancer with liver metastasis

DOI: 10.3969/j.issn.1001-5256.2022.03.023

  • Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China

Research funding:

Natural Science Foundation of Liaoning Province (20180551193);

Natural Science Foundation of Liaoning Province (2020-MS-181);

The 345 Talent Project Plan of Shengjing Hospital (40B)

More Information
  • Corresponding author: XU Feng, xufengsjh@126.com(ORCID: 0000-0001-9985-6527)
  • Received Date: 2021-07-11
  • Accepted Date: 2021-08-27
  • Published Date: 2022-03-20
    Abstract
  •   Objective  To investigate the clinical effect of simultaneous surgical resection of hepatic and pancreatic lesions versus systemic chemotherapy in treatment of resectable pancreatic cancer with liver metastasis (PCLM).  Methods  A retrospective analysis was performed for related data of the patients with PCLM who were admitted to Shengjing Hospital of China Medical University from January 2013 to May 2020, and the patients with resectable PCLM were screened out and then divided into surgery group and chemotherapy group. The propensity score matching (PSM) method was used to reduce the impact of data bias and confounding factors. The independent samples t-test or the Mann- Whitney U test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between two groups. The Kaplan-Meier method was used to calculate survival time, and the log-rank test was used for evaluation. The univariate and multivariate Cox regression models were used to investigate the independent risk factors for survival.  Results  A total of 56 patients with resectable PCLM were screened out, with 33 patients in the surgery group and 23 patients in the chemotherapy group, and there were 15 patients in each group after PSM. The surgery group had a significantly shorter median overall survival time than the chemotherapy group before PSM (6.6 months vs 10.4 months, χ2=4.476, P=0.034) and after PSM (6.4 months vs 10.5 months, χ2=4.309, P=0.038). The multivariate Cox regression analysis showed that poorly differentiated tumor (hazard ratio [HR]=4.945, 95% confidence interval [CI]: 1.980-12.348, P=0.001) and absence of postoperative chemotherapy (HR=3.670, 95%CI: 1.437-9.376, P=0.007) were independent risk factors for poor prognosis in patients with PCLM.  Conclusion  Compared with chemotherapy, simultaneous surgical resection of hepatic and pancreatic lesions fails to prolong the overall survival time of patients with resectable PCLM. Patients with poorly differentiated tumor and those without postoperative chemotherapy tend to have poor prognosis.

     

    • FullText(HTML)
  • loading
    • References(26)
  • [1]
    JIN T, DAI C, XU F. Surgical and local treatment of hepatic metastasis in pancreatic ductal adenocarcinoma: Recent advances and future prospects[J]. Ther Adv Med Oncol, 2020, 12: 1758835920933034. DOI: 10.1177/1758835920933034.
    [2]
    JIN TQ, XU F, DAI CL, et al. Progress in surgical and interventional treatment of pancreatic cancer with liver metastases[J]. J Hepatopancreatobiliary Surg, 2018, 30(6): 518-521. DOI: 10.11952/j.issn.1007-1954.2018.06.022.

    金添强, 徐锋, 戴朝六. 胰腺癌肝转移手术及介入治疗新进展[J]. 肝胆胰外科杂志, 2018, 30(6): 518-521. DOI: 10.11952/j.issn.1007-1954.2018.06.022.
    [3]
    TACHEZY M, GEBAUER F, JANOT M, et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis[J]. Surgery, 2016, 160(1): 136-144. DOI: 10.1016/j.surg.2016.02.019.
    [4]
    DVNSCHEDE F, WILL L, von LANGSDORF C, et al. Treatment of metachronous and simultaneous liver metastases of pancreatic cancer[J]. Eur Surg Res, 2010, 44(3-4): 209-213. DOI: 10.1159/000313532.
    [5]
    YANG YM, LIU GN. Surgical resection or palliative care for pancreatic cancer with liver oligometastasis[J]. Chin J Dig Surg, 2021, 20(4): 376-380. DOI: 10.3760/cma.j.cn115610-20210219-00082.

    杨尹默, 刘光年. 胰腺癌合并肝脏寡转移: 联合切除还是姑息治疗[J]. 中华消化外科杂志, 2021, 20(4): 376-380. DOI: 10.3760/cma.j.cn115610-20210219-00082.
    [6]
    YANG J, ZHANG J, LUI W, et al. Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection[J]. HPB (Oxford), 2020, 22(1): 91-101. DOI: 10.1016/j.hpb.2019.05.015.
    [7]
    Chinese College of Surgeons; Section of Gastrointestinal Surgery, Branch of Surgery, Chinese Medical Association; Section of Colorectal Surgery, Branch of Surgery, Chinese Medical Association, et al. China guideline for diagnosis and comprehensive treatment of colorectal liver metastases (version 2020)[J]. Chin J Gastrointestinal Surg, 2021, 24(1): 1-13. DOI: 10.3760/cma.j.cn.441530-20201225-00680.

    中国医师协会外科医师分会, 中华医学会外科分会胃肠外科学组, 中华医学会外科分会结直肠外科学组, 等. 中国结直肠癌肝转移诊断和综合治疗指南(V2020)[J]. 中华胃肠外科杂志, 2021, 24(1): 1-13. DOI: 10.3760/cma.j.cn.441530-20201225-00680.
    [8]
    AKGVL Ö, ÇETINKAYA E, ERSÖZŞ, et al. Role of surgery in colorectal cancer liver metastases[J]. World J Gastroenterol, 2014, 20(20): 6113-6122. DOI: 10.3748/wjg.v20.i20.6113.
    [9]
    XU F, TANG B, JIN TQ, et al. Current status of surgical treatment of colorectal liver metastases[J]. World J Clin Cases, 2018, 6(14): 716-734. DOI: 10.12998/wjcc.v6.i14.716.
    [10]
    CONROY T, DESSEIGNE F, YCHOU M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med, 2011, 364(19): 1817-1825. DOI: 10.1056/NEJMoa1011923.
    [11]
    KANG J, HWANG I, YOO C, et al. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: Retrospective analysis[J]. Invest New Drugs, 2018, 36(4): 732-741. DOI: 10.1007/s10637-018-0598-5.
    [12]
    ANDREOU A, KNITTER S, KLEIN F, et al. The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma[J]. Surg Oncol, 2018, 27(4): 688-694. DOI: 10.1016/j.suronc.2018.09.004.
    [13]
    YU X, GU J, FU D, et al. Dose surgical resection of hepatic metastases bring benefits to pancreatic ductal adenocarcinoma? A systematic review and meta-analysis[J]. Int J Surg, 2017, 48: 149-154. DOI: 10.1016/j.ijsu.2017.10.066.
    [14]
    GLEISNER AL, ASSUMPCAO L, CAMERON JL, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?[J]. Cancer, 2007, 110(11): 2484-2492. DOI: 10.1002/cncr.23074.
    [15]
    SHI HJ, JIN C, FU DL. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability[J]. World J Gastroenterol, 2016, 22(45): 10024-10037. DOI: 10.3748/wjg.v22.i45.10024.
    [16]
    CRIPPA S, BITTONI A, SEBASTIANI E, et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?[J]. Eur J Surg Oncol, 2016, 42(10): 1533-1539. DOI: 10.1016/j.ejso.2016.06.398.
    [17]
    HACKERT T, NIESEN W, HINZ U, et al. Radical surgery of oligometastatic pancreatic cancer[J]. Eur J Surg Oncol, 2017, 43(2): 358-363. DOI: 10.1016/j.ejso.2016.10.023.
    [18]
    SCHNEITLER S, KRÖPIL P, RIEMER J, et al. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection[J]. World J Gastroenterol, 2015, 21(20): 6384-6390. DOI: 10.3748/wjg.v21.i20.6384.
    [19]
    FRIGERIO I, REGI P, GIARDINO A, et al. Downstaging in stage IV pancreatic cancer: A new population eligible for surgery?[J]. Ann Surg Oncol, 2017, 24(8): 2397-2403. DOI: 10.1245/s10434-017-5885-4.
    [20]
    SEELIG SK, BURKERT B, CHROMIK AM, et al. Pancreatic resections for advanced M1-pancreatic carcinoma: The value of synchronous metastasectomy[J]. HPB Surg, 2010, 2010: 579672. DOI: 10.1155/2010/579672.
    [21]
    HUA YQ, WANG P, ZHU XY, et al. Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: An analysis of safety and efficacy[J]. Pancreatology, 2017, 17(6): 967-973. DOI: 10.1016/j.pan.2017.08.072.
    [22]
    VOGL TJ, MOHAMED SA, ALBRECHT MH, et al. Transarterial chemoembolization in pancreatic adenocarcinoma with liver metastases: MR-based tumor response evaluation, apparent diffusion coefficient (ADC) patterns, and survival rates[J]. Pancreatology, 2018, 18(1): 94-99. DOI: 10.1016/j.pan.2017.11.014.
    [23]
    REN G, WANG YJ. Advances in radiotherapy for pancreatic cancer from 2019 to 2020[J]. J Clin Hepatol, 2021, 37(3): 733-736. DOI: 10.3969/j.issn.1001-5256.2021.03.048.

    任刚, 王颖杰. 2019年-2020年胰腺癌放射治疗新进展[J]. 临床肝胆病杂志, 2021, 37(3): 733-736. DOI: 10.3969/j.issn.1001-5256.2021.03.048.
    [24]
    YANG YM, ZHAO XD. Evaluation of neoadjuvant therapy for pancreatic cancer: is it the best choice?[J]. Chin J Dig Surg, 2020, 19(1): 41-45. DOI: 10.3760/cma.j.issn.1673-9752.2020.01.006.

    杨尹默, 赵旭东. 肯定还是否定: 胰腺癌新辅助治疗[J]. 中华消化外科杂志, 2020, 19(1): 41-45. DOI: 10.3760/cma.j.issn.1673-9752.2020.01.006.
    [25]
    JIN KZ, LUO GP, CHENG H, et al. Comprehensive treatment of pancreatic cancer with liver metastases[J]. J Hepatobiliary Surg, 2019, 27(1): 16-20. DOI: 10.3969/j.issn.1006-4761.2019.01.005.

    金凯舟, 罗国培, 程合, 等. 胰腺癌肝转移的综合治疗[J]. 肝胆外科杂志, 2019, 27(1): 16-20. DOI: 10.3969/j.issn.1006-4761.2019.01.005.
    [26]
    OUYANG HQ, PAN ZY, MA WD, et al. Multidisciplinary treatment and survival analysis for 497 cases of pancreatic cancer with liver metastases[J]. Natl Med J China, 2016, 96(6): 425-430. DOI: 10.3760/cma.j.issn.0376-2491.2016.06.003.

    欧阳华强, 潘战宇, 马维东, 等. 胰腺癌肝转移497例多学科治疗临床分析[J]. 中华医学杂志, 2016, 96(6): 425-430. DOI: 10.3760/cma.j.issn.0376-2491.2016.06.003.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (674) PDF downloads(45) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return